Article
Endocrinology & Metabolism
Jingya Wang, Jennifer M. Cooper, Krishna Gokhale, Dionisio Acosta-Mena, Samir Dhalla, Nathan Byne, Joht Singh Chandan, Astha Anand, Kelvin Okoth, Anuradhaa Subramanian, Mansoor N. Bangash, Thomas Jackson, Dawit Zemedikun, Tom Taverner, Wasim Hanif, Sandip Ghosh, Parth Narendran, Konstantinos A. Toulis, Abd A. Tahrani, Rajendra Surenthirakumaran, Nicola J. Adderley, Shamil Haroon, Kamlesh Khunti, Christopher Sainsbury, G. Neil Thomas, Krishnarajah Nirantharakumar
Summary: The study found that current prescription of metformin was not associated with increased risk of COVID-19 or COVID-19-related mortality in patients with diabetes. It is safe to continue prescribing metformin to improve glycemic control in these patients.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Review
Endocrinology & Metabolism
Sun H. Kim, Ipsa Arora, Daniel S. Hsia, William C. Knowler, Erin LeBlanc, Eleftherios Mylonakis, Richard Pratley, Anastassios G. Pittas
Summary: There is evidence suggesting that infection with SARS-CoV-2 can lead to long-term sequelae, including diabetes. This mini-review examines the evolving literature on new-onset diabetes after COVID-19 (NODAC). Current evidence suggests that COVID-19 increases the risk of developing diabetes, but the exact causality is uncertain due to study limitations and the evolving nature of the pandemic. COVID-19 may have direct and indirect effects on pancreatic beta-cell function and insulin sensitivity.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Review
Immunology
Amir Bahador Boroumand, Mahtab Forouhi, Farzaneh Karimi, Arman Soltani Moghadam, Leila Ghanbari Naeini, Pajman Kokabian, Delaram Naderi
Summary: Immunogenicity of COVID-19 vaccines is generally lower in patients with diabetes mellitus compared to healthy individuals. Age, type of diabetes, BMI, glycemic control, and eGFR are factors that affect antibody response.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Endocrinology & Metabolism
Shi Jin, Weina Hu
Summary: COVID-19, named by WHO in February 2020, quickly became a global pandemic by March 2020, posing higher risks for patients with comorbidities like diabetes. Currently, there is no approved standard treatment protocol for COVID-19 cases with pre-existing diabetes.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Endocrinology & Metabolism
Salvatore Corrao, Karen Pinelli, Martina Vacca, Massimo Raspanti, Christiano Argano
Summary: This review discusses the prevalence, pathophysiological mechanisms, and outcomes of COVID-19 infection in people with diabetes, proposing a rationale for using drugs prescribed in patients with diabetes and providing pragmatic clinical recommendations for dealing with COVID-19 in this patient population.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Cardiac & Cardiovascular Systems
Hayder M. Al-kuraishy, Ali I. Al-Gareeb, M. Alblihed, Susana G. Guerreiro, Natalia Cruz-Martins, Gaber El-Saber Batiha
Summary: COVID-19 caused by SARS-CoV-2 may lead to extrapulmonary manifestations like diabetes mellitus and hyperglycemia, with SARS-CoV-2 infecting the pancreas through ACE2. The severity of SARS-CoV-2 infection in DM patients is associated with preexisting comorbidities and inflammation disorders. Some antidiabetic agents may reduce SARS-CoV-2 severity through modulation of the ACE2 receptor expression.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Article
Virology
Faisal Aziz, Hannah Stocher, Alexander Brauer, Christian Ciardi, Martin Clodi, Peter Fasching, Mario Karolyi, Alexandra Kautzky-Willer, Carmen Klammer, Oliver Malle, Felix Aberer, Erich Pawelka, Slobodan Peric, Claudia Ress, Caren Sourij, Lars Stechemesser, Harald Stingl, Thomas Stulnig, Norbert Tripolt, Michael Wagner, Peter Wolf, Andreas Zitterl, Othmar Moser, Christian Schelkshorn, Susanne Kaser, Harald Sourij
Summary: This study assessed the predictive performance of inflammatory, hepatic, coagulation, and cardiac biomarkers in patients with prediabetes and diabetes mellitus hospitalized for COVID-19 in Austria. Troponin T showed excellent predictive performance, while NT-proBNP showed good predictive performance for assessing in-hospital mortality in patients with diabetes mellitus hospitalized with COVID-19.
Review
Medicine, General & Internal
Ting Zhang, Qimin Mei, Zhaocai Zhang, Joseph Harold Walline, Yecheng Liu, Huadong Zhu, Shuyang Zhang
Summary: There is an increased risk of new-onset diabetes after COVID-19 infection, especially within the first 3 months. Patients of all ages and genders are at higher risk for developing diabetes after COVID-19.
Article
Endocrinology & Metabolism
Masahiro Yoshikawa, Kensuke Asaba, Tomohiro Nakayama
Summary: Using a two-sample MR approach, the study found that T2DM has a significant causal effect on the risk of COVID-19 outcomes in the East Asian population, independent of the effect of BMI.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Chemistry, Medicinal
Hayder M. Al-Kuraishy, Ali Al-Gareeb, Sarah M. Albogami, Sabatier Jean-Marc, Eman Hassan Nadwa, Amin A. Hafiz, Walaa A. Negm, Marwa Kamal, Mohammed Al-Jouboury, Engy Elekhnawy, Gaber El-Saber Batiha, Michel De Waard
Summary: Type 2 diabetes mellitus is a potential risk factor for severe COVID-19, but the combination of metformin and sitagliptin may provide more beneficial effects in reducing the severity of the disease.
Article
Endocrinology & Metabolism
Ruediger Gross, Alexander Kleger
Summary: As emerging clinical analyses suggest an increased risk of new-onset diabetes following COVID-19, a causal link and underlying mechanisms are yet to be established. Persistence of hyperglycaemia after disease regression and the potential infection of non-pancreatic tissue are adding another layer of complexity to the relationship between COVID-19 and diabetes mellitus.
News Item
Multidisciplinary Sciences
Clare Watson
Summary: The increase in childhood type 1 diabetes has provided researchers with new opportunities to investigate the cause of the disease.
Review
Endocrinology & Metabolism
Lingli Xie, Ziying Zhang, Qian Wang, Yangwen Chen, Dexue Lu, Weihua Wu
Summary: This article systematically analyzed the relationship between viral cell surface receptors and SARS-CoV-2 infection risk, emphasizing the importance of ACE2 in virus infection and COVID-19 pathogenesis. It also discussed the mutual influence between diabetes and COVID-19, along with treatment options, and reviewed the significance of different forms of ACE2 and gender in COVID-19 susceptibility and severity.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Virology
Hassan M. Al-Emran, Shaminur Rahman, Md Shazid Hasan, Rubayet Ul Alam, Ovinu Kibria Islam, Ajwad Anwar, Md Iqbal K. Jahid, Anwar Hossain
Summary: This study compares the nasopharyngeal microbiome of COVID-19-infected diabetic and nondiabetic patients, and finds a link between dysbiosis of bacterial community in diabetic patients and severe consequences.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Medicine, General & Internal
Mohammed Badedi, Abdulrahman Muhajir, Awaji Alnami, Hussain Darraj, Aymn Alamoudi, Yasir Agdi, Ahoud Mujayri, Atif Ageeb
Summary: This study assessed the severity and clinical characteristics of COVID-19 among Saudi adults with type 2 diabetes mellitus in the Jazan region. The results showed that patients with type 2 diabetes had longer disease duration and higher blood glucose levels. Most patients had clinical symptoms, but some chose to self-isolate at home. Patients with type 2 diabetes were more likely to be admitted to the intensive care unit and had a higher mortality rate compared to those without diabetes.
Review
Dermatology
Eleni Papadokostaki, Evangelos Rizos, Stelios Tigas, Evangelos N. Liberopoulos
INTERNATIONAL JOURNAL OF LOWER EXTREMITY WOUNDS
(2020)
Article
Immunology
Eleni Papadokostaki, Anastasios Tentolouris, Ioanna A. Anastasiou, Mina Psichogiou, Evangelia Iliaki, Ioanna Eleftheriadou, Angelos Hatzakis, Nikolaos Tentolouris
Summary: The mRNA-based BNT162b2 vaccine showed high efficacy against severe SARS-CoV-2 infection. Limited data is available regarding the immune response in people with diabetes after vaccination with the BNT162b2 vaccine. This study found that almost 17% of participants with diabetes did not develop adequate immune response after the first dose, but the response became high and similar between participants with and without diabetes after the second dose, and remained stable even two months after the second dose. There was no significant difference in antibody levels between participants with and without diabetes throughout the study. At least two doses of the BNT162b2 vaccine are required for sufficient and sustainable immune response in people with diabetes.
Article
Endocrinology & Metabolism
Eleni Papadokostaki, Evangelos Liberopoulos
CASE REPORTS IN ENDOCRINOLOGY
(2019)
